Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.775p 0.75p 0.80p 0.775p 0.775p 0.775p 3,069,873 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.7 -0.1 - 22.29

Sareum Holdings PLC Result of AGM

14/12/2017 11:01am

UK Regulatory (RNS & others)


Sareum (LSE:SAR)
Historical Stock Chart

1 Year : From Nov 2017 to Nov 2018

Click Here for more Sareum Charts.

TIDMSAR

RNS Number : 3728Z

Sareum Holdings PLC

14 December 2017

 
 (AIM: SAR)   14 December 2017 
 

Sareum Holdings plc

("Sareum" or "the Company")

Results of AGM

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting today and all resolutions were duly passed.

-Ends-

For further information, please contact:

 
Sareum Holdings plc 
Tim Mitchell                           01223 497 700 
WH Ireland Limited (Nominated Adviser and 
 Co-Broker) 
Chris Fielding / James Sinclair-Ford   020 7220 1666 
Hybridan LLP (Co-Broker) 
Claire Noyce                           020 3764 2341 
Citigate Dewe Rogerson (Media 
 enquiries) 
Shabnam Bashir/ Mark Swallow/ 
 David Dible                           020 7282 9571 
 

Notes for editors:

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company's drug discovery technology platform (SKIL(R) - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGOKQDPKBDDCBD

(END) Dow Jones Newswires

December 14, 2017 06:01 ET (11:01 GMT)

1 Year Sareum Chart

1 Year Sareum Chart

1 Month Sareum Chart

1 Month Sareum Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:gb D:20181118 01:45:31